Analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS - Get Free Report) in a note issued to investors on Saturday. The firm set a "sell" rating on the biotechnology company's stock.
Cellectis Stock Up 0.5 %
Shares of NASDAQ CLLS traded up $0.01 during mid-day trading on Friday, hitting $2.01. The company had a trading volume of 16,645 shares, compared to its average volume of 46,283. Cellectis has a one year low of $0.96 and a one year high of $3.77. The company has a market capitalization of $111.72 million, a PE ratio of -1.45 and a beta of 3.09. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.39. The firm has a 50-day simple moving average of $2.18 and a two-hundred day simple moving average of $2.37.
Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.05. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. The company had revenue of $9.50 million for the quarter, compared to analyst estimates of $6.00 million. On average, equities analysts expect that Cellectis will post -0.54 EPS for the current year.
Institutional Investors Weigh In On Cellectis
A number of large investors have recently added to or reduced their stakes in CLLS. Long Focus Capital Management LLC increased its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock valued at $8,634,000 after purchasing an additional 130,000 shares during the last quarter. Baillie Gifford & Co. raised its holdings in Cellectis by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company's stock valued at $2,192,000 after acquiring an additional 10,605 shares during the period. Principal Financial Group Inc. raised its holdings in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock valued at $817,000 after acquiring an additional 12,467 shares during the period. XTX Topco Ltd bought a new stake in shares of Cellectis during the second quarter worth approximately $29,000. Finally, First Affirmative Financial Network acquired a new position in shares of Cellectis in the third quarter valued at approximately $45,000. Institutional investors own 63.90% of the company's stock.
About Cellectis
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Further Reading
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
